It is not one drug but an entire class of targeted therapies that is reshaping how neurologists treat myasthenia gravis, and the shift has been swift. Since December 2021, when the FDA approved efgartigimod (Vyvgart) as the first neonatal Fc receptor (FcRn) blocker for generalized myasthenia gravis, the treatment landscape has expanded to include complement inhibitors, B-cell depleting agents, and additional FcRn blockers — giving clinicians more than six targeted options where, just a decade ago, only broad immunosuppressants existed. For patients who spent years cycling through steroids and plasma exchange with inconsistent relief, these drugs represent a genuine turning point.
The speed of change is hard to overstate. A 2025 review published in the Journal of Neurology identified five developments transforming MG care: FcRn inhibitors, complement inhibitors, B-cell depletion, standardized outcome measures like the MG-ADL scale, and steroid-sparing treatment goals. What follows is a detailed look at the specific drugs behind this shift, how they compare, where they fall short, and what patients and caregivers focused on neurological health should understand about a disease that, while distinct from dementia, shares the broader challenge of navigating complex treatment decisions in neurology.
Table of Contents
- Which Drugs for Myasthenia Gravis Are Changing the Way Neurologists Practice?
- How FcRn Inhibitors Work and Where Their Limits Lie
- Nipocalimab and the Push Toward Broader Access
- Complement Inhibitors Versus FcRn Blockers — How Do Clinicians Choose?
- B-Cell Depletion and the Goal of Steroid-Free Remission
- What the Cost Landscape Looks Like for Patients and Families
- What Comes Next in Myasthenia Gravis Treatment
- Conclusion
- Frequently Asked Questions
Which Drugs for Myasthenia Gravis Are Changing the Way Neurologists Practice?
Three drug classes are driving the transformation. FcRn inhibitors — efgartigimod (Vyvgart) and nipocalimab (Imaavy) — work by accelerating the destruction of harmful IgG antibodies that attack the neuromuscular junction. Complement inhibitors such as zilucoplan (Zilbrysq), eculizumab (Soliris), and ravulizumab (Ultomiris) block a different part of the immune cascade, specifically the C5 complement protein. And the B-cell depleting therapy inebilizumab (Uplizna), approved for MG in December 2025, targets the immune cells that produce those damaging antibodies in the first place.
Before these therapies existed, neurologists relied on corticosteroids, azathioprine, mycophenolate, and periodic intravenous immunoglobulin infusions. These treatments suppressed the immune system broadly, which meant patients traded muscle weakness for infection risk, weight gain, bone loss, and other steroid side effects — sometimes for decades. The newer drugs are designed to intervene at specific points in the autoimmune process, which in clinical trials has translated to faster symptom improvement and meaningful reductions in steroid dependence. Consider the comparison: in the Phase 3 ADAPT trial for efgartigimod, 68 percent of treated patients showed clinically meaningful improvement compared with 30 percent on placebo after a single four-week treatment cycle. The older approach of titrating prednisone doses over months, watching for diabetes and osteoporosis, and hoping for gradual stabilization now has a concrete alternative — and in many cases, several alternatives.
How FcRn Inhibitors Work and Where Their Limits Lie
FcRn inhibitors represent the most active area of MG drug development right now. The neonatal Fc receptor normally recycles IgG antibodies, keeping their levels high in the bloodstream. By blocking this receptor, drugs like efgartigimod and nipocalimab cause pathogenic IgG antibodies to be cleared more rapidly, reducing the autoimmune attack on neuromuscular junctions. Efgartigimod, manufactured by argenx, was the pioneer. Its FDA approval in December 2021 covered adults with acetylcholine receptor (AChR) antibody-positive generalized MG. By January 2023, 2,215 patients had initiated Vyvgart treatment, and half of those who completed a first cycle went on to start a second, suggesting that clinicians and patients found the results worth continuing.
A November 2025 study from UNC School of Medicine found that efgartigimod was safe and effective across all subtypes of generalized MG, not just the originally approved antibody-positive population. In January 2026, the FDA accepted a Priority Review application to expand efgartigimod’s label to AChR antibody-seronegative patients — a group that has historically had no approved targeted therapy. The PDUFA target date is May 10, 2026. However, these drugs are not without significant limitations. Efgartigimod carries an annual net cost of approximately $225,000, and while copay assistance of up to $25,000 per year is available, that figure still places the therapy out of reach for many patients without robust insurance coverage. Additionally, because FcRn inhibitors reduce IgG levels broadly — not just the pathogenic antibodies — patients may become more susceptible to infections. If a patient is already immunocompromised or has recurrent infections, the risk-benefit calculation shifts considerably, and neurologists must weigh these factors carefully for each individual.
Nipocalimab and the Push Toward Broader Access
The newest FcRn inhibitor, nipocalimab (sold as Imaavy), earned FDA approval on April 29, 2025. Developed by Johnson & Johnson, it carries the broadest population label of any FcRn blocker currently on the market, covering adults and pediatric patients ages 12 and older who are either AChR- or MuSK-antibody positive. That MuSK-positive inclusion matters. MuSK-antibody MG is less common but often more aggressive, with prominent bulbar symptoms — difficulty swallowing, speaking, and breathing — that can be particularly dangerous. In the Phase 3 Vivacity-MG3 trial, nipocalimab demonstrated a statistically significant improvement on the MG-ADL scale of -4.7 points compared with -3.3 for placebo (P = 0.002).
The drug reduced serum IgG levels by up to 75 percent from the first dose, with that reduction sustained over 24 weeks. It is administered via intravenous infusion, available in 300 mg and 1,200 mg single-dose vials. Johnson & Johnson’s patient assistance program allows commercially insured patients to pay as little as zero dollars per infusion, which attempts to address the cost barrier that has limited uptake of other targeted therapies. For families already navigating the complexities of neurological care — whether for myasthenia gravis, dementia, or other conditions — the pediatric indication is noteworthy. Juvenile MG is relatively rare, and having an FDA-approved targeted therapy available for patients as young as 12 fills a gap that previously required off-label use of adult treatments with limited evidence in younger populations.
Complement Inhibitors Versus FcRn Blockers — How Do Clinicians Choose?
Complement inhibitors attack the disease from a different angle entirely. Rather than clearing pathogenic antibodies, they block the complement protein C5, preventing the terminal complement cascade from damaging the neuromuscular junction. Eculizumab (Soliris) was the first complement inhibitor approved for AChR-positive MG in 2017, followed by the longer-acting ravulizumab (Ultomiris), which reduced infusion frequency. Zilucoplan (Zilbrysq), approved by the FDA in October 2023 and developed by UCB, brought a practical advantage that neither of its predecessors offered: it is the first and only once-daily subcutaneous self-administered targeted C5 complement inhibitor for generalized MG. In the Phase 3 RAISE study, zilucoplan demonstrated rapid, statistically significant improvement in both patient- and clinician-reported outcomes at Week 12 across mild-to-severe disease.
Dosed at 0.3 mg/kg daily via subcutaneous injection, it eliminates the need for infusion center visits — a meaningful quality-of-life improvement for patients who are already managing chronic illness. The tradeoff is safety. Complement inhibitors carry an increased risk of meningococcal infection because the complement system is a critical defense against Neisseria meningitidis. Patients must receive meningococcal vaccination before starting treatment with zilucoplan, and the most common side effects occurring in more than 10 percent of patients include injection site reactions, upper respiratory tract infections, and diarrhea. FcRn inhibitors do not carry this same meningococcal risk, which may make them preferable for patients who are unwilling or unable to accept that particular vulnerability. Neither class is universally superior — the choice depends on antibody subtype, patient preference for dosing route, infection history, and insurance coverage.
B-Cell Depletion and the Goal of Steroid-Free Remission
The approval of inebilizumab (Uplizna) for generalized MG in December 2025 added a third mechanism of action to the targeted therapy arsenal. Manufactured by Amgen, Uplizna was already approved for two other conditions, making MG its third FDA indication. It works by depleting CD19-positive B cells — the immune cells responsible for producing the pathogenic antibodies that drive MG. The Phase 3 MINT trial results were compelling, particularly for the steroid-sparing goal that has become central to modern MG management. Patients treated with inebilizumab showed an MG-ADL score change of -4.2 compared with -2.2 for placebo. More strikingly, 87.4 percent of patients reduced their steroid doses to 5 mg or less of prednisone by Week 26, with sustained benefits at 52 weeks.
After two initial loading doses, the maintenance schedule requires only two infusions per year — a dosing convenience that few other MG therapies can match. The European Commission followed with its own approval in February 2026. A word of caution, though. B-cell depletion is a more profound immunological intervention than either FcRn blockade or complement inhibition. Patients who receive inebilizumab are at increased risk for infections and may have impaired vaccine responses. For older adults or individuals with comorbidities — including those managing concurrent cognitive decline or dementia — this immunosuppressive burden is not trivial and requires careful coordination between neurologists, primary care physicians, and geriatricians.
What the Cost Landscape Looks Like for Patients and Families
Cost remains one of the most significant barriers to accessing these therapies. Efgartigimod’s approximate annual net cost of $225,000 is broadly representative of the targeted biologic class, though individual out-of-pocket expenses vary widely depending on insurance type, manufacturer assistance programs, and regional formulary decisions.
Nipocalimab’s zero-dollar copay program for commercially insured patients and efgartigimod’s $25,000-per-year copay assistance help, but patients on Medicare or Medicaid often face different coverage structures and may encounter prior authorization hurdles that delay treatment initiation. The practical reality is that a patient diagnosed with generalized MG today may have six or more targeted therapies available on paper but only one or two that their insurance will approve without an extended appeals process. Neurologists increasingly find themselves spending as much time navigating payer requirements as they do making clinical decisions — a frustration that is hardly unique to MG but is amplified by the rapid expansion of expensive treatment options.
What Comes Next in Myasthenia Gravis Treatment
The trajectory is clear and encouraging. Efgartigimod’s pending Priority Review for seronegative generalized MG, with a decision expected by May 10, 2026, could open targeted therapy to a population that has been excluded from every approved indication so far. If approved, it would represent the first therapy specifically indicated for patients whose disease is real but whose standard antibody tests come back negative — a validation that many seronegative patients have waited years to see.
Beyond individual drug approvals, the broader shift in MG care reflects a pattern that is beginning to influence other autoimmune neurological conditions as well. The combination of mechanism-specific drugs, steroid-sparing treatment strategies, standardized patient-reported outcome measures, and growing real-world evidence is creating a model that researchers hope to replicate in conditions ranging from neuromyelitis optica to autoimmune encephalitis. For those of us who follow brain health and neurological care closely, the MG story is a reminder that targeted science, when matched with rigorous trials, can fundamentally change what it means to live with a chronic neurological disease.
Conclusion
Myasthenia gravis treatment has undergone a transformation that would have been difficult to imagine a decade ago. From the first FcRn inhibitor approval in 2021 through the latest B-cell depleting therapy and expanded population labels in 2025 and 2026, patients now have access to drugs that target specific immune pathways rather than suppressing the entire immune system. The clinical data — 68 percent response rates with efgartigimod, 87 percent steroid reduction with inebilizumab, self-administered daily dosing with zilucoplan — represents a genuine leap forward in both efficacy and quality of life.
For patients, caregivers, and families navigating neurological diagnoses of any kind, the MG story carries a broader lesson. Targeted therapies work best when patients and clinicians have honest conversations about goals, risks, costs, and preferences. Whether the choice is an FcRn blocker, a complement inhibitor, or a B-cell depleting agent, the decision should be individualized — and the fact that such a decision is now possible at all is the real change in neurology practice.
Frequently Asked Questions
What is myasthenia gravis, and how does it relate to brain health?
Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes muscle weakness and fatigue. While it affects the neuromuscular junction rather than the brain directly, it falls under neurology care and shares the treatment complexity and caregiver burden associated with other neurological conditions including dementia.
Which myasthenia gravis drug has the broadest FDA-approved population?
Nipocalimab (Imaavy), approved in April 2025, has the broadest label among targeted MG therapies. It covers adults and pediatric patients ages 12 and older who are AChR- or MuSK-antibody positive.
Can any of these drugs be self-administered at home?
Zilucoplan (Zilbrysq) is the first and only once-daily subcutaneous self-administered targeted C5 complement inhibitor for generalized MG, dosed at 0.3 mg/kg daily. It does not require infusion center visits but does require meningococcal vaccination before starting treatment.
How much do targeted myasthenia gravis therapies cost?
Annual costs for targeted MG biologics are substantial. Efgartigimod (Vyvgart) has an approximate annual net cost of $225,000, with copay assistance up to $25,000 per year available. Nipocalimab offers a program allowing commercially insured patients to pay as little as zero dollars per infusion. Costs vary significantly based on insurance type and coverage.
What is the steroid-sparing benefit of inebilizumab (Uplizna)?
In the Phase 3 MINT trial, 87.4 percent of patients treated with inebilizumab reduced their steroid doses to 5 mg or less of prednisone by Week 26, with benefits sustained at 52 weeks. After initial loading doses, maintenance requires only two infusions per year.
Is there a targeted therapy for seronegative myasthenia gravis patients?
Not yet, but efgartigimod is under Priority Review by the FDA for AChR antibody-seronegative generalized MG, with a decision expected by May 10, 2026. If approved, it would be the first targeted therapy indicated for this underserved population.
